Shandong Jincheng Pharmaceutical Group Co., Ltd. Class A

Shandong Jincheng Pharmaceutical Group Co., Ltd. Class A

SSZSE:300233
11.11
CNY
-0.08
(-0.71%)
0.41EPS
32.96P/E
5.22BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.73
4.25
4.69
5.61
7.5
7.64
7.15
7.63
8.14
9.11
9.11
8.91
7.43
7.44
Basic EPS, GAAP
0.27
0.44
0.68
0.63
0.77
0.67
0.52
-1.26
0.28
0.71
0.45
0.52
0.12
0.41
Free Cash Flow per Basic Share
-0.27
0.24
0.19
0.33
-0.11
0.01
0.55
0.71
0.16
-0.31
0.83
0.41
0.59
- -
Dividend per Share
0.15
0.17
0.21
0.2
0.19
0.24
0.31
0.26
0.27
0.27
0.22
0.35
0.44
0.17
Book Value per Share
4.22
4.42
5.1
5.67
9.83
10.2
10.34
8.78
8.76
9.31
9.68
9.81
9.54
9.77
Tangible Book Value per Share
3.9
4
4.44
4.9
5.45
5.99
6.68
6.86
6.79
7.23
7.48
7.85
7.76
8.15
Basic Weighted Avg Shares
244
247
251
253
372
394
391
388
386
385
388
378
368
381
Sales/Revenue/Turnover
909
1,051
1,179
1,420
2,788
3,008
2,795
2,962
3,138
3,506
3,538
3,373
2,737
2,834
Operating Margin (%)
11.57
13.37
15.41
10.6
13.26
17.62
17.09
12.84
8.94
11.58
8.17
8.82
4.99
8.62
Depreciation Expense
57
71
83
89
152
169
179
198
224
256
308
319
322
- -
Net Income, GAAP
65
109
171
159
286
264
203
-489
108
273
175
197
44
157
Effective Tax Rate (%)
19.77
11.86
2.26
7.97
14.85
23.72
32.09
- -
37.38
17.37
14.24
22.62
45.82
25.93
Profit Margin (%)
7.11
10.34
14.51
11.22
10.27
8.77
7.27
-16.5
3.44
7.8
4.94
5.83
1.61
5.54
Working Capital
294
230
356
443
884
952
1,013
1,071
723
607
769
1,027
864
1,075
LT Debt
30
33
14
27
14
162
206
319
272
274
350
359
89
17
Total Equity
1,022
1,117
1,310
1,504
3,938
4,087
4,085
3,467
3,439
3,659
3,781
3,832
3,724
3,814
Return on Invested Capital (%)
5.19
8.24
10.76
8.38
9.63
6.34
2.27
- -
3.23
7.01
4.52
4.81
1.09
- -
Return on Capital (%)
6.11
9.06
12.49
10.34
9.76
5.82
4.41
- -
2.67
6.74
4.11
4.61
1.23
- -
Return on Common Equity (%)
6.47
10.17
14.19
11.68
10.8
6.7
5.04
-13.03
3.16
7.81
4.77
5.26
1.19
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
315
316
198
LT Borrowings
17
17
16
LT Finance Leases
4
2
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
384
384
384
Market Capitalization
5,340
4,760
5,221

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,175
2,169
2,107
Cash, Cash Equivalents & STI
956
963
943
Accounts Receivable, Net
544
457
408
Inventories
447
487
489
Total Current Liabilities
1,255
1,137
1,032
Payables & Accruals
- -
- -
- -
ST Debt
315
316
198
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.26%
1.49%
-2.82%
Free Cash Flow
833.07%
-150.63%
42.08%
Net Income, GAAP
-36.84%
-13.99%
-77.55%
Sales/Revenue/Turnover
11.87%
-0.99%
-18.87%
Total Cash Common Dividend
14.45%
12.93%
23.42%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
932
827
757
858
3,373
2025
722
638
- -
805
2,737
2026
750
697
582
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.22
0.13
0.05
0.12
0.52
2025
0.09
0.02
- -
0.03
0.12
2026
0.15
0.21
0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.21
0.11
0.01
0.35
2025
0.15
0.16
- -
0.01
0.44
2026
0.01
0.16
- -
- -
- -

Company Description

CEO
Jiaquan Li
Full Time Employees
3,515
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No.1 Shuangshan Road Zibo SD China 255188
IPO Date
Jun 13, 2011
Business
Shandong Jincheng Pharmaceutical Group Co., Ltd operates primarily in the pharmaceutical industry, specializing in the research, development, manufacturing, and distribution of a broad range of pharmaceutical products. Its core product portfolio includes active pharmaceutical ingredients (APIs), bulk drugs, chemical pharmaceuticals, traditional Chinese medicines, and healthcare products. The company manufactures pharmaceutical intermediates, APIs for cardiovascular, anti-inflammatory, and antimicrobial agents; traditional Chinese medicine extracts; formulated medicines such as tablets, capsules, and injections; as well as nutritional supplements and health-related products. Founded in 2001 and headquartered in Jinan, Shandong Province, China, the company serves domestic and international markets through its extensive sales network and subsidiary operations. It is engaged in various business segments including pharmaceutical technology, chemical synthesis, and pharmaceutical healthcare product services, targeting hospitals, pharmacies, and healthcare institutions primarily in China while expanding its footprint globally. In recent years, Shandong Jincheng Pharmaceutical Group has implemented significant strategic initiatives including forming partnerships to enhance its pharmaceutical research and development capabilities, launching new product lines in advanced drug formulations, and expanding its manufacturing capacity to meet rising demand. The company has also pursued acquisitions to broaden its product portfolio and has focused on innovation in traditional Chinese medicine integrated with modern pharmaceutical technologies, reflecting a strategic shift toward higher value-added pharmaceutical products and greater market diversification. Overall, Shandong Jincheng Pharmaceutical Group Co., Ltd is a comprehensive pharmaceutical enterprise that combines traditional and modern pharmaceutical products, scientific research services, and healthcare solutions with an emphasis on innovation and market expansion.